Bolin Liu, MD

Professor

Departments of Interdisciplinary Oncology and Genetics
Stanley S. Scott Cancer Center
Telephone: 504-210-3328
Fax: 504-210-2970
Email: bliu2@lsuhsc.edu

Degrees

1987 M.D. in Medicine
Beijing Medical University, Beijing, China

1994 M.S. in Molecular Biology
Institute of Hematology, Chinese Academy of Medical
Sciences and Peking Union of Medical Colleges,
Tianjin, China

2002 Post Doctoral Fellow in Cancer Biology
The University of Texas MD Anderson Cancer Center
Houston, TX

Bio

Dr. Bolin Liu obtained his M.D. from Beijing Medical University in 1987 and Master of Science from Chinese Academy of Medical Science in 1994. From 1998-2002, he received extensive postdoctoral training in cancer biology at MD Anderson Cancer Center. In late 2002, Dr. Liu joined the University of Oklahoma Health Sciences Center as a Research Assistant Professor. In 2006, he was recruited to the Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, where he became an independent investigator in 2007 and was promoted to Associate Professor in 2015. Since November 2018, Dr. Liu has been a Professor at the Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center - New Orleans. Dr. Liu’s laboratory focuses on studying the molecular mechanism of drug resistance and tumor metastasis in breast cancer and non-small cell lung cancer (NSCLC).

Research Interests

Receptor tyrosine kinase (RTK)-initiated cell signaling in drug resistance and tumor metastasis of breast cancer and non-small cell lung cancer (NSCLC)
Epigenetic regulation of gene expression in tumor progression of triple negative breast cancer (TNBC) and NSCLC
Identification of novel therapeutic targets and effective combinatorial approaches for HER2-positive breast cancer, TNBC, and NSCLC

Selected Publications

Hui Lyu, Defu Hou, Hao Liu, Sanbao Ruan, Congcong Tan, Jiande Wu, Chindo Hicks, and Bolin Liu. Upregulation of HER3 confers a new therapeutic strategy to augment the efficacy of panobinostat in claudin-low triple-negative breast cancer. NPJ Precision Oncology 2023; 7: 72

Hui Lyu, Fei Shen, Sanbao Ruan, Congcong Tan, Jundong Zhou, Ann D. Thor, and Bolin Liu. HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel. Cancer Cell International 2023; 23: 204

Margaret E Larsen, Hui Lyu, and Bolin Liu. HER3-targeted therapeutic antibodies and antibody-drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors. Chinese Medical Journal - Pulmonary and Critical Care Medicine 2023; 1: 11-17

Hao Liu, Sanbao Ruan, Margaret E. Larsen, Congcong Tan, Bolin Liu,*, and Hui Lyu*. Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo. Biological Procedures Online 2023; 25: 19 *Corresponding authors

Hao Liu*, Hui Lyu, Guanmin Jiang, Danyang Chen, Sanbao Ruan, Shuang Liu, Lukun Zhou, Minqiang Yang, shanshan Zeng, Zhimin He, Hongsheng Wang, Hongsheng Li, Guopei Zheng, and Bolin Liu*. ALKBH5-mediated m⁶A demethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targeted therapy in breast cancer. Cancer Research 2022; 82: 3974-3986 *Corresponding authors

Shuang Liu, Erik V. Polsdofer, Lukun Zhou, Sanbao Ruan, Hui Lyu, Defu Hou, Hao Liu, Ann D. Thor, Zhimin He, and Bolin Liu. Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC. Molecular Therapy: Oncolytics 2021; 21: 303-314

Liyun Luo, Zhijie Zhang, Ni Qiu, Li Ling, Xiaoting Jia, Ying Song, Hongsheng Li, Jiansheng Li, Hui Lyu, Hao Liu, Zhimin He*, BolinLiu*, and Guopei Zheng*. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. Nature Communications 2021; 12: 2699 *Corresponding authors

Xiaolong Liu, Shuang Liu, Hui Lyu, Adam I. Riker, Yamin Zhang, and Bolin Liu. Development of effective therapeutics targeting HER3 for cancer treatment. Biological Procedures Online 2019; 21:5

Hui Lyu, Shuiliang Wang, Jingcao Huang, Bolun Wang, Zhimin He, and Bolin Liu.Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.Cancer Letters 2018; 420: 97-108

Hui Lyu, XiaoHe Yang, Susan M. Edgerton, Ann D. Thor, Xiaoying Wu, Zhimin He, and Bolin Liu. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. Oncotarget 2016;7(3): 2921-2935

Ying Wu, Hui Lyu, Hongbing Liu, Xuefei Shi, Yong Song, and Bolin Liu. Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. Scientific Reports 2016;6, 31093

Shuiliang Wang, Jingcao Huang, Hui Lyu, Choon-Kee Lee, Jianming Tan, Jianxiang Wang, and Bolin Liu. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death & Disease 2013;4: e556

Shuiliang Wang, Jingcao Huang, Hui Lyu, Bo Cai, Xiaoping Yang, Fang Li, Jianming Tan, Susan M. Edgerton, Ann D Thor, Choon-Kee Lee, and Bolin Liu. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Research 2013;15:R101

Jingcao Huang, Shuiliang Wang, Hui Lyu, Bo Cai, XiaoHe Yang, Jianxiang Wang, and Bolin Liu. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Molecular Cancer 2013;12:134

Xiaoping Huang, Shuiliang Wang, Choon-Kee Lee, XiaoHe Yang, and Bolin Liu. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Letters 2011;307(1):72-9

Shuiliang Wang, Xiaoping Huang, Choon-Kee Lee, and Bolin Liu. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010;29: 4225–4236

Xiaoping Huang, Lizhi Gao, Shuiliang Wang, James L. McManaman, Ann D. Thor, Xiaohe Yang, Francisco J. Esteva, and Bolin Liu. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to Herceptin. Cancer Research 2010;70(3):1204-1214

Xiaoping Huang, Lizhi Gao, Shuiliang Wang, Choon-Kee Lee, Peter Ordentlich, and Bolin Liu. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via downregulation of erbB3 expression. Cancer Research 2009;69(21):8403-8411

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .